Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $37.5 million versus the consensus estimate of $40.85 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.